RRML - Advances in detection of anti-dsDNA antibodies
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- November 2024 -
 
Towards appropriate training f... 31
Recomandările naționale ale ... 28
Biomarkers of acute kidney inj... 23
A comprehensive review of glyc... 20
Agreement between different eG... 19
Investigation of cytokine chan... 19
Expressions of vascular endoth... 17
Role of Th1/Th2 imbalance medi... 16
Small patients, big challenges... 9
The frequency of EGFR gene mut... 8

Log in

Concept, Design & Programming
Dr. Adrian Man
   
 
Nr. 1(1)/2005
XML
TXT

Advances in detection of anti-dsDNA antibodies

Manole Cojocaru


Abstract:

In clinical practice, antibodies to double-stranded deoxyribonucleic acid (dsDNA) are among the commonly used antinuclear (ANA) antibodies. The serological correlation between dsDNA and clinical outcome is an area of controversy. The dsDNA continue to show a high disease correlation with patients suffering from SLE, and it is possible that they play a role in its pathogenesis. Additionally, they have also been used clinically to monitor disease activity. Antibodies to DNA can be divided into 2 groups: those that react to denatured or single-stranded DNA (ssDNA) and those recognizing double-stranded DNA (dsDNA). Tests for anti-ssDNA antibodies have limited usefulness. In contrast, anti-dsDNA antibodies are relatively specific (95%) for SLE, making them useful for diagnosis. A negative test does not rule out the disease. Numerous methods have been devised to detect anti-dsDNA antibodies: indirect immunofluorescence, immunoenzymatic assay, counter immunoelectrophoresis, immuno- and western blotting. An immunofluorescent assay (IFA) is now available for the detection of anti-dsDNA antibodies in human serum. This IFA anti-dsDNA test kit uses Crithidia luciliae as a substrate. The optimally shaped Crithidia luciliae provide easy identification of the kinetoplast which contains dsDNA. The use a positive control not only validates the test but helps in the identification of the kinetoplast. Positive specimens are titred to an end-point determined as the last dilution to show kinetoplast fluorescence. A poor prognostic sign in SLE is the presence of anti-dsDNA antibodies indicating an increased likelihool of major organ involvement (e.g., renal disease or vasculitis). About 65% of SLE patients with active disease have anti-dsDNA antibodies but less than 5% have elevated levels when disease is quiescent. More than 80% of patients with lupus nephritis have elevated levels

Keywords: anti-dsDNA antibodies,SLE,disease activity,laboratory tests

 
  PDF Download full text PDF
(331 KB)
     
 
How to cite
Cojocaru M. Advances in detection of anti-dsDNA antibodies . Rev Romana Med Lab. 2005;1(1):38-43